1. Home
  2. BCSF vs STTK Comparison

BCSF vs STTK Comparison

Compare BCSF & STTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Bain Capital Specialty Finance Inc.

BCSF

Bain Capital Specialty Finance Inc.

N/A

Current Price

$11.09

Market Cap

838.7M

Sector

Finance

ML Signal

N/A

Logo Shattuck Labs Inc.

STTK

Shattuck Labs Inc.

N/A

Current Price

$6.84

Market Cap

792.9M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
BCSF
STTK
Founded
2015
2016
Country
United States
United States
Employees
N/A
N/A
Industry
Finance/Investors Services
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
838.7M
792.9M
IPO Year
2015
2020

Fundamental Metrics

Financial Performance
Metric
BCSF
STTK
Price
$11.09
$6.84
Analyst Decision
Hold
Strong Buy
Analyst Count
4
11
Target Price
$12.63
★ $14.67
AVG Volume (30 Days)
474.3K
★ 864.5K
Earning Date
11-09-2026
11-05-2026
Dividend Yield
★ 17.12%
N/A
EPS Growth
N/A
★ 53.02
EPS
★ 0.27
N/A
Revenue
N/A
★ $1,000,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$41.76
★ N/A
Revenue Growth
★ N/A
N/A
52 Week Low
$10.95
$1.70
52 Week High
$14.70
$8.33

Technical Indicators

Market Signals
Indicator
BCSF
STTK
Relative Strength Index (RSI) 35.19 60.14
Support Level N/A $6.75
Resistance Level $13.74 $7.75
Average True Range (ATR) 0.20 0.39
MACD 0.02 0.12
Stochastic Oscillator 16.28 90.10

Price Performance

Historical Comparison
BCSF
STTK

About BCSF Bain Capital Specialty Finance Inc.

Bain Capital Specialty Finance Inc is an externally managed, closed-end, non-diversified management investment company. The company's objective is to provide risk-adjusted returns and current income to investors by investing in middle-market companies. Its portfolio of investments includes First Lien Senior Secured Loan, Preferred Equity, Equity Interest, Warrants, and Second Lien Senior Secured Loan, and others.

About STTK Shattuck Labs Inc.

Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.

Share on Social Networks: